LifeVantage to Announce First Quarter Fiscal Year 2019 Results on November 1, 2018


SALT LAKE CITY, Oct. 18, 2018 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its first quarter ended September 30, 2018, after the stock market closes on Thursday, November 1, 2018. The Company will hold a conference call for investors at 2:30 p.m. Mountain Daylight Time (4:30 p.m. Eastern Daylight Time) that same day.

Investors interested in participating in the live call can dial (888) 394-8218 from the U.S. or international callers can dial (323) 701-0225. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 8, 2018, by dialing (844) 512-2921 from the U.S. and entering confirmation code 2572167, or (412) 317-6671 from international locations, and entering confirmation code 2572167.

There also will be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations. The webcast will be archived for approximately 30 days.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics – a new science dedicated to biohacking the human aging code. The company is engaged in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin care products, including Protandim®, a line of scientifically-validated dietary supplements; TrueScience®, a line of Nrf2 infused skin care products; Petandim™ for Dogs, a companion pet supplement formulated to combat oxidative stress in dogs; Axio® Smart Energy Drink mixes; PhysIQ™, a Smart Weight Management System; and Omega+, a 3-in-1 fish oil supplement. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.

Investor Relations Contact:

Scott Van Winkle
Managing Director, ICR
(617) 956-6736
scott.vanwinkle@icrinc.com